Thibaut Roulon
Director/Board Member chez NH THERAGUIX SAS
Profil
Thibaut Roulon is currently a Director at LimFlow SA, and also holds Director positions at BPIFrance Investissement SAS, Advicenne SA, Imcheck Therapeutics SAS, NH TherAguix SAS, AlgoTherapeutix SAS, ADEMTECH SA, and Step Pharma SAS.
He previously held Director positions at Poxel SA, Sangamo Therapeutics France SAS, Sensorion SA, Biom'Up SA, Gensight Biologics SA, GamaMabs Pharma SA, and CorWave SA. Prior to his Director roles, he was a Chargé d'Affaires at Bioam Gestion SA. Roulon received his undergraduate degree from École Centrale Paris and his doctorate from Université Pierre et Marie Curie.
Postes actifs de Thibaut Roulon
| Sociétés | Poste | Début |
|---|---|---|
| ADVICENNE | Director/Board Member | 29/04/2011 |
| NH THERAGUIX SAS | Director/Board Member | 22/02/2019 |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Director/Board Member | - |
ADEMTECH SA
 ADEMTECH SA Miscellaneous Commercial ServicesCommercial Services ADEMTECH SA specializes in developing and manufacturing magnetic nanoparticles for diagnostic and scientific research applications. The firm produces magnetic nanoparticles for concentration, separation, purification, microfluidic device integration and identification of molecules and specific cells. The company was founded in 2000 and is headquartered in Pessac, France. | Director/Board Member | - |
LimFlow SA
 LimFlow SA Medical SpecialtiesHealth Technology LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France. | Director/Board Member | - |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Director/Board Member | - |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Director/Board Member | 04/12/2019 |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Private Equity Analyst | 14/10/2010 |
Anciens postes connus de Thibaut Roulon
| Sociétés | Poste | Fin |
|---|---|---|
Bioam Gestion SA
 Bioam Gestion SA Investment ManagersFinance Bioam Gestion SA (BG) is a venture capital investment firm established in 2000 at the initiative of the French Ministry of Research and located in Paris. The firm invests capital from public and private sources. BG manages FCPR venture capital funds focused on the biotechnology sector. The firm's sponsors include the three French national research institutes: CNRS (fundamental research), INRA (agriculture-oriented research) and INSERM (medical research), as well as financial institutions such as CDC Enterprises, AXA Private Equity, a regional savings bank, and corporations. | Private Equity Analyst | 02/07/2010 |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Thibaut Roulon
| École Centrale Paris | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| POXEL | Health Technology |
| SENSORION | Health Technology |
| ADVICENNE | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Bioam Gestion SA
Bioam Gestion SA Investment ManagersFinance Bioam Gestion SA (BG) is a venture capital investment firm established in 2000 at the initiative of the French Ministry of Research and located in Paris. The firm invests capital from public and private sources. BG manages FCPR venture capital funds focused on the biotechnology sector. The firm's sponsors include the three French national research institutes: CNRS (fundamental research), INRA (agriculture-oriented research) and INSERM (medical research), as well as financial institutions such as CDC Enterprises, AXA Private Equity, a regional savings bank, and corporations. | Finance |
ADEMTECH SA
ADEMTECH SA Miscellaneous Commercial ServicesCommercial Services ADEMTECH SA specializes in developing and manufacturing magnetic nanoparticles for diagnostic and scientific research applications. The firm produces magnetic nanoparticles for concentration, separation, purification, microfluidic device integration and identification of molecules and specific cells. The company was founded in 2000 and is headquartered in Pessac, France. | Commercial Services |
| Université Pierre et Marie Curie | Consumer Services |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Finance |
Sangamo Therapeutics France SAS
 Sangamo Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics France SAS is a biotechnology company, which engages in developing platforms for T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases. The company was founded on April 12, 2001, and is headquartered in Valbonne-Sophia Antipolis, France. | Commercial Services |
Biom'Up SA
 Biom'Up SA Medical SpecialtiesHealth Technology Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France. | Health Technology |
GamaMabs Pharma SA
 GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Health Services |
CorWave SA
 CorWave SA Medical SpecialtiesHealth Technology CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France. | Health Technology |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Health Technology |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Health Technology |
LimFlow SA
LimFlow SA Medical SpecialtiesHealth Technology LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France. | Health Technology |
NH TherAguix SAS
 NH TherAguix SAS Pharmaceuticals: MajorHealth Technology NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G?raldine Le Duc, Olivier Tillement and Fran?ois Lux in on December 11, 2015 and is headquartered in Meylan, France. | Health Technology |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |
